MDT changes
Pick any two versions below to diff them.
- Price
- $94.75 → $93.03(−1.8%)
- Discount
- 6% to 23% → 8% to 25%(+2.0 pts)
- Recent events
- 2026-10-15: The MiniMed exchange offer settled, and Medtronic said that the separation of MiniMed is complete. On October 14, 2026, Medtronic also named Michael Marinaro, who leads the Medical Surgical portfolio in the Americas and global commercial operations, as President of Medtronic. He also oversees Greater China and reports to CEO Geoff Martha. 2026-10-14: Medtronic announced the final results of the MiniMed exchange offer. Holders tendered about 297.5 million Medtronic shares, so the offer was oversubscribed. Medtronic exchanged all of its remaining 252.8 million MiniMed shares for 55.0 million Medtronic shares, and it no longer owns MiniMed shares. 2026-09-14: Medtronic started an offer to exchange shares of MiniMed Group for outstanding Medtronic shares, to complete the separation of its diabetes business. 2026-09-01: Medtronic reported Q1 fiscal 2027 results. Revenue was $9.76 billion, up 13.7% organic, with about $570 million from an extra fiscal week. Cardiovascular grew 18.9%, and cardiac ablation grew 88%. Non-GAAP EPS was $1.45. Medtronic raised its fiscal 2027 guidance to organic revenue growth of 7.25% to 7.75% and non-GAAP EPS of $5.94 to $6.00. 2026-07-16: Medtronic completed the acquisition of SPR Therapeutics. It had completed the acquisition of Scientia Vascular on June 12, 2026. 2026-03-09: MiniMed Group, Medtronic's diabetes business, completed its initial public offering. Medtronic kept a controlling stake until the exchange offer in October 2026.